Aurobindo Pharma Ltd

NSE: AUROPHARMA · BSE: 524804 · Pharmaceuticals & Biotechnology · 63 announcements

Aurobindo Pharma Ltd news stories on ALFA NewsRead the news →

Share price: ₹1,680.80
Market cap: ₹97,621 Cr
Revenue (annual): ₹33,653 Cr
Net profit (annual): ₹3,505 Cr
P/E (TTM): 24.8×Sector 47.4×
Promoter holding: 51.88%+0.06% QoQ
FII holding: 16.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

24 Apr 2026 16:30 IST BSE

Aurobindo Pharma Debt & Borrowing: ₹580 Cr

Aurobindo Pharma Ltd submitted its initial disclosure under the SEBI Large Corporate framework for FY 2026-27. The company reported outstanding borrowings of ₹580.00 Crore as of March 31, 2026, and maintains an IND AA+/Stable credit rating. The filing confirms compliance with debt market borrowing requirements.

Value: ₹580.0 Cr

Read the filing ↗